On September 9, 2026, the Company entered into an underwriting agreement with Guggenheim Securities LLC and sold (i) 500,000 shares of Class A Common Stock, (ii) “pre-funded warrants” to purchase upon exercise, up to 2,005,513 shares of its Class A Common Stock, and (iii) common warrants to purchase upon exercise, up to 6,992,382 shares of its Class A Common Stock, which represented all of the securities offered in the offering. The Company received gross proceeds of approximately $500.0 million related to this sale and incurred related costs of approximately $11.2 million. In September 2026, the Company issued 500,000 shares of Class A Common Stock, 2,005,513 pre-funded warrants, and 6,992,382 common warrants. As of September 30, 2026, none of the pre-funded or common warrants have been exercised.


	Underlying Shares of Class A Common Stock	Exercise Price		Expiration Date

Pre-funded warrants	2,005,513	$	0.1000	September 10, 2051
Common warrants
Warrant Series A
Warrant Series A - Tranche 1	1,101,989	$	226.8625	September 10, 2028
Warrant Series A - Tranche 2	1,101,989	$	226.8625	November 12, 2028
Warrant Series B
Warrant Series B - Tranche 1	918,324	$	272.2350	September 10, 2029
Warrant Series B - Tranche 2	918,324	$	272.2350	November 12, 2029
Warrant Series C
Warrant Series C - Tranche 1	787,135	$	317.6075	September 10, 2030
Warrant Series C - Tranche 2	787,135	$	317.6075	November 12, 2030
Warrant Series D
Warrant Series D - Tranche 1	688,743	$	362.9800	September 10, 2031
Warrant Series D - Tranche 2	688,743	$	362.9800	November 12, 2031
Total common warrants	6,992,382

The pre-funded warrants are classified as stockholders’ equity and the common warrants are classified as liabilities and remeasured at each reporting period. Issuance costs of $4.6 million allocated to the common warrants were expensed and included in Selling, General, and Administrative costs, and the $6.6 million issuance costs allocated to the equity-classified instruments were recorded as a reduction of Excess of Capital over Par Value.